GLP-1 Drugs and Kidney Outcomes in CKD

A systematic review published in Diabetes, Obesity and Metabolism in September 2026 pooled 13 randomised controlled trials covering 97,428 participants, 31,846 of them with confirmed chronic kidney disease, and found that GLP-1 receptor agonists including semaglutide cut major cardiovascular events by 16% and a composite kidney endpoint by 21% in that CKD population^[1]. Both figures carry a high GRADE certainty rating. The part of the paper that puts semaglutide at the top of a league table is a different kind of finding, and the authors themselves call it exploratory.

What the pooled trials reported

Kaur and Singh searched MEDLINE, Embase, Cochrane CENTRAL and Web of Science through March 2025, keeping only randomised trials that enrolled adults with CKD, defined as an eGFR below 60 mL/min/1.73 m2 or a urine albumin-to-creatinine ratio of 30 mg/g or higher, and that compared a GLP-1 receptor agonist against placebo for at least 26 weeks^[1]. Across those trials, three-point MACE fell 16% (hazard ratio 0.84, 95% CI 0.79 to 0.89) and a kidney composite harmonised to KDIGO definitions fell 21% (HR 0.79, 95% CI 0.73 to 0.86)^[1]. Kidney failure risk was 28% lower (HR 0.72) and urine albumin-to-creatinine ratio dropped 26%^[1]. The review reported no excess risk of acute kidney injury^[1].

The subgroup question about SGLT2 inhibitors got a clean answer. The benefit held whether or not participants were already taking one, with an interaction p value of 0.41^[1]. On this evidence the two drug classes add up rather than cancel out.

The semaglutide ranking is not head-to-head evidence

Semaglutide ranked highest in the network meta-analysis, with a SUCRA value of 78.4%^[1]. SUCRA stands for surface under the cumulative ranking curve, a statistic that summarises how often a treatment comes out on top across simulated comparisons. It is not a trial result. A network meta-analysis compares drugs that were never tested against each other, by routing each one through its own placebo comparison, and the authors label that part of their work exploratory^[1]. Semaglutide sits at the top of the list in part because it has the largest dedicated CKD trial behind it, not because anyone randomised patients to semaglutide against a competing GLP-1 drug and counted kidney failures. The ranking points to which agent a future head-to-head trial should test first, and it stops there.

The trial the review builds towards

The review describes the GLP-1 evidence base in CKD as culminating in the FLOW trial^[1]. FLOW randomised 3,533 people with type 2 diabetes and CKD to subcutaneous semaglutide 1.0 mg weekly or placebo and followed them for a median of 3.4 years^[2]. The primary composite of major kidney disease events was 24% lower on semaglutide, 331 versus 410 first events (HR 0.76, 95% CI 0.66 to 0.88, P = 0.0003)^[2]. Cardiovascular death was 29% lower (HR 0.71, 95% CI 0.56 to 0.89), major cardiovascular events 18% lower (HR 0.82, 95% CI 0.68 to 0.98), and all-cause mortality 20% lower (HR 0.80, 95% CI 0.67 to 0.95)^[2]. Annual eGFR decline was 1.16 mL/min/1.73 m2 less steep than on placebo^[2]. Entry required a diagnosis of type 2 diabetes.

What the labels say, and where they differ

Regulators have moved on this, unevenly. The US prescribing information for Ozempic now carries three indications, the third being to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease^[3]. Europe reads differently. Its authorisation covers treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise, and the EMA product overview sets out no kidney indication^[4]. Ozempic is prescription-only across the EU^[4]. Our semaglutide regulatory summary tracks that split, and the country pages for the United States, the United Kingdom and Germany carry the local wording.

The gap matters for how you read the pooled numbers. A licensed kidney indication means a regulator reviewed the trial data and accepted that the drug changes kidney outcomes in a defined population. An absence of that wording on the EU label does not mean the European regulator rejected the evidence, only that the indication has not been added there. Neither position tells you anything about GLP-1 agonists sold outside a pharmacy chain, which sit in a separate category entirely.

What we don't yet know

The abstract does not report how many of the 31,846 participants with confirmed CKD had kidney disease without type 2 diabetes, and the trial the review builds towards enrolled only people with type 2 diabetes^[1][2]. Neither the US nor the EU label extends to CKD outside diabetes^[3]. Reading this review as evidence for non-diabetic kidney disease goes past what the data covers.

The literature search also closed in March 2025, so anything reported after that date is absent from the pool^[1]. And a pooled hazard ratio is an average across trials with different entry thresholds, different agents and different follow-up lengths. It describes a class effect. It does not tell any individual what their own risk reduction would be.

What this means if you have CKD

None of this is a treatment plan. The trials administered fixed weekly doses under trial monitoring, in populations selected by specific eGFR and albuminuria thresholds, and the analysis reports averages across those populations^[1]. If you have chronic kidney disease and are already taking a GLP-1 receptor agonist, or are wondering whether one belongs in your regimen alongside an SGLT2 inhibitor, that is a conversation for the clinician who can see your eGFR trend and your albuminuria numbers. What the pooled data does establish is that the kidney effect in this class is measurable and consistent enough to have reached a US label^[3].

This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.